ＩＱＶＩＡサービシーズジャパン（株）

What ＩＱＶＩＡサービシーズジャパン（株） does

IQVIA Services Japan K.K. (IQVIAサービシーズジャパン合同会社) is a Tokyo-based operating subsidiary of IQVIA Inc. (NYSE: IQV) delivering integrated life sciences services across Japan. Its portfolio is organized around eight core service lines: Clinical Development (oncology, CNS, regenerative medicine, medical devices), Real World Evidence, Market Data/RWD, Consulting, Safety/Regulatory/Quality, Connected Healthcare, Technology Solutions, and Contract Sales Organization (CSO) services. Within CSO, IQVIA pioneered the category in Japan 20 years ago and retains category leadership. The company serves five primary customer verticals: pharmaceutical companies, medical device manufacturers, healthcare providers and hospitals, insurance payers (保険者), and insurance-registered pharmacies (保険薬局), with pharmaceuticals and medical devices as primary segments.

Underpinning these services is the IQVIA.ai unified agentic AI platform, developed in partnership with NVIDIA and hosted on AWS as the Preferred Agentic Cloud Provider, alongside a stack of supporting assets: Orchestrated Clinical Trials (OCT), SmartSolve RIM for regulatory information management, IQVIA Regulatory Intelligence, Real World Data Platforms, IQVIA Remote Detailing, Customer Engagement Platform, IQVIA Hospital Data Platform, and a Disease Onset Risk Prediction Model for payers. The business combines decades of proprietary Japanese longitudinal healthcare data with global IQVIA expertise to span the full product lifecycle from research through commercialization.

Revenue is generated through a mix of professional services (clinical development, consulting, CSO medical-representative outsourcing) and subscription/recurring streams (RWE platforms, market data, safety/regulatory, connected healthcare). Pricing is not publicly disclosed and follows quote-based enterprise B2B arrangements. The go-to-market is direct enterprise field sales to pharma and medtech clients, supplemented by industry-event presence and thought-leadership content. The Japan entity sits within a multi-entity subsidiary structure (IQVIA Solutions Japan, IQVIA Site Solutions Japan, IQVIA Laboratories Japan) under publicly traded parent IQVIA Inc., and individual Japan entity financials are not separately disclosed.

Name

ＩＱＶＩＡサービシーズジャパン（株）

Legal name

IQVIAサービシーズ ジャパン合同会社

Website

https://iqvia.co.jp

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

IQVIA Services Japan K.K. is a Tokyo-based subsidiary of IQVIA Inc. (NYSE: IQV) providing clinical development, real-world evidence, market data, consulting, regulatory, connected healthcare, and CSO services to pharmaceutical companies, medical device firms, hospitals, payers, and pharmacies in Japan.

Ownership category

akta.pro rank

Product category

Life Sciences Services

NAICS

Professional, Scientific, and Technical Services (54), Other Scientific and Technical Consulting Services (54169), Other Scientific and Technical Consulting Services (541690)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industries

Regulatory Information Management (RIM) & Submission Publishing Software (HLAGAJAL), Data Analytics & Business Intelligence Services (BPAHALAC)

Keywords

• Clinical research services
• Real-world evidence
• Pharmaceutical market data
• Regulatory consulting
• Contract sales organization

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Professional Services - Clinical Development: Comprehensive clinical development services including oncology, CNS, and regenerative medicine product development, clinical trials, regulatory consulting, and laboratory services for pharmaceutical and medical device companies
2. Real World Evidence Solutions: Evidence generation, healthcare data transformation, health economics, and regulatory safety services leveraging proprietary data networks and analytics capabilities
3. Market Data and Analytics: Healthcare reference databases and market data services providing pharmaceutical sales tracking and market intelligence for the Japanese market
4. Consulting Services: Management consulting, primary intelligence, and real-world data consulting to support strategic decision-making for life sciences companies
5. Safety, Regulatory, and Quality Services: Pharmacovigilance, post-marketing regulatory consulting, and quality compliance solutions
6. Connected Healthcare Solutions: Healthcare solutions for medical institutions, insurance payers, and pharmacies including data-driven health support and hospital data platforms
7. CSO (Contract Sales Organization) Services: Outsourced medical representative services, remote detailing, patient support programs, and healthcare sales support platform

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

IQVIA Services Japan provides life sciences services to pharmaceutical, biotechnology, medical device, healthcare provider, and payer organizations in Japan. Its offerings span clinical development, real-world evidence generation, market data and analytics, consulting, safety/regulatory/pharmacovigilance, connected healthcare, technology solutions, and contract sales organization (CSO) services for pharmaceuticals.

Product overview

IQVIA Japan operates as a platform-plus-modules architecture offering integrated life sciences solutions. The core portfolio encompasses eight major service lines: Clinical Development (covering oncology, CNS, regenerative medicine, and medical devices), Real World Evidence (evidence networks, genomics, data transformation), Market Data/RWD, Consulting & Services, Safety/Regulatory/Quality, Connected Healthcare, Technology Solutions, and CSO (Contract Sales Organization) services. Key supporting products include SmartSolve RIM (regulatory information management), IQVIA.ai (agentic AI platform), IQVIA Remote Detailing, Disease Onset Risk Prediction Model, IQVIA Hospital Data Platform, and IQVIA Regulatory Intelligence portal. The company recently rebranded its laboratory subsidiary to IQVIA Laboratories Japan and launched the IQVIA.ai unified agentic AI platform in March 2026, which serves as a foundational AI infrastructure across all service offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Services

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature8 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Charles River LaboratoriesflagshipStrategic or Co-development Partner · 1 February 2026Agreement to acquire drug discovery assets from Charles River Laboratories to expand IQVIA's end-to-end drug discovery capabilities, enabling a more comprehensive offering from early research through clinical development.
• Boehringer IngelheimflagshipStrategic or Co-development Partner · 1 January 2026Long-term strategic collaboration to transform commercial data infrastructure, leveraging IQVIA's data and analytics capabilities to support Boehringer Ingelheim's commercial operations and market intelligence capabilities.
• NVIDIAcoreTechnology or Integration · 1 December 2025Strategic partnership leveraging NVIDIA's AI infrastructure and GPU technology for the IQVIA.ai unified agentic AI platform, enabling enhanced operational efficiency and decision-making capabilities across the life sciences sector through advanced AI applications.
• Amazon Web Services (AWS)coreTechnology or Integration · 1 December 2025AWS selected as the Preferred Agentic Cloud Provider for IQVIA's next-generation AI platform, providing cloud infrastructure to power AI capabilities and analytics solutions for the life sciences industry.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ICON plc: Global CRO offering clinical development, biometric, laboratory, and consulting services to pharma and medical-device sponsors. Direct competitor to IQVIA Japan's clinical development and laboratory services, with comparable end-to-end trial execution capabilities.
• Veeva Systems: Life-sciences cloud software vendor with RIM, clinical, and commercial suites. Direct peer to SmartSolve RIM and IQVIA's technology solutions layer, competing for the same pharma technology budgets.
• Parexel International: Large global CRO providing clinical development, regulatory, real-world evidence, and commercialization services. Direct peer across IQVIA Japan's clinical, regulatory, and CSO lines, with overlapping pharmaceutical customer base.
• Medidata Solutions (Dassault Systèmes): Clinical trial technology platform (EDC/CTMS/eCOA) serving pharma and CROs. Competes with IQVIA's Orchestrated Clinical Trials (OCT) technology stack and is a key clinical-informatics alternative for Japanese sponsors.
• Charles River Laboratories: Global CRO/non-clinical lab services partner and recent counterparty for IQVIA's drug-discovery asset acquisition. Comparable in discovery, preclinical, and clinical lab services for pharma and medical-device clients.
• Labcorp (Covance Drug Development): Integrated CRO and diagnostics business via the Covance franchise. Competes with IQVIA Japan's clinical development, central laboratory, and real-world evidence offerings for the same pharmaceutical sponsors.
• Syneos Health: Clinical and commercial solutions provider combining CRO services with contract sales organization capabilities. Closely mirrors IQVIA Japan's combined clinical development + CSO positioning for pharma customers.
• PPD (Thermo Fisher Scientific): Thermo Fisher's pharmaceutical services division, one of the largest global CROs. Competes head-on with IQVIA Japan on clinical trial execution, biopharma laboratory services, and real-world evidence.

Regional players

• EPS Holdings: Japan-based CRO and healthcare solutions provider offering clinical development, SMO, and data services. Regional peer competing for the same Japanese pharma and medical-device clinical and post-marketing work.
• CMIC Holdings: Japan's largest domestic CRO with clinical development, CMO, CSO, and site-support services. Direct Japan-local competitor to IQVIA's CSO and clinical trial businesses, especially for Japanese pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/IQVIA_japan
• Facebookfacebook.com/IQVIAJapan
• LinkedInlinkedin.com/company/%EF%BD%89%EF%BD%91%EF%BD%96%EF%BD%89%EF%BD%81%E3%82%B5%E3%83%BC%E3%83%93%E3%82%B7%E3%83%BC%E3%82%BA%E3%82%B8%E3%83%A3%E3%83%91%E3%83%B3%EF%BC%88%E6%A0%AA%EF%BC%89

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ＩＱＶＩＡサービシーズジャパン（株）